Stirling goes back to the drawing board
Monday, 07 March, 2005
Stirling Products (ASX:STI) will extend its proof-of-concept studies to include a more direct delivery method after analysis of levels of its beta agonist ST810, a single enantiomer form of salbutamol, in the bloodstream of merino lambs showed that the growth promoter was not getting into the bloodstream.
Significantly, the positive control, a mixed enantiomer form of salbutamol, also failed to get into the bloodstream.
Managing director Calvin London said that as a result, sufficient plasma levels of the drug were not achieved, and no significant physical effects such as reduction in fat or increase in muscle were observed.
Now, the company plans to look at using a more precise controlled release delivery directly into the tissue. The follow-on study is expected to begin in April.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
